POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.
about
Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.Comparing Papanicolau smear, visual inspection with acetic acid and human papillomavirus cervical cancer screening methods among HIV-positive women by immune status and antiretroviral therapyhTERT promoter activity and CpG methylation in HPV-induced carcinogenesisComparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assayHPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study.comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders.Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer.Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways.Bead-based multiplex genotyping of human papillomaviruses.Importance of HPV Genotyping for the Screening, Therapy and Management of Cervical NeoplasiasHuman papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic reviewPAX1/SOX1 DNA methylation and cervical neoplasia detection: a Taiwanese Gynecologic Oncology Group (TGOG) study.Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model.The indicating FTA elute cartridge a solid sample carrier to detect high-risk HPV and high-grade cervical lesions.Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.Biomarkers of cervical dysplasia and carcinomaEvaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens.Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate.Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients.Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing.Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.Molecular Epidemiology of High-Risk Types of Human Papillomaviruses (16, 18) in Pap-Smear, the North East of Iran.Clinical relevance of human papillomavirus testing in cytopathology.HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflowsHPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia.Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women.Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening.Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening.High-risk HPV type-specific clearance rates in cervical screening.Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The NetherlandsRoutine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting.The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation studyPractice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition.Development and characterization of the cobas human papillomavirus test.Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination.The future of cytopathology in Europe. Will the wider use of HPV testing have an impact on the provision of cervical screening?
P2860
Q30863996-83132B06-40D9-4801-A332-A337D5FA76C1Q33555812-4F72EBA9-460D-4893-82B4-6257D70E66CEQ33599338-705C6B05-ECB2-4202-9D15-B9EBA20157C7Q33704719-4486FA2B-C0F7-4DDB-A6D2-4748BE42D867Q33704883-472ACCAE-1A77-4C75-B874-56AC87BBFB9CQ33721970-E7EF113D-68D3-4748-B71D-C6FA0D1476B0Q33856287-3E950848-E805-4725-85CC-D350D95955BBQ34049709-FC2A447A-C352-4F38-B5DD-3DE850C0C261Q34117301-4B2503F4-9BF4-4148-92B5-2C9CC3845149Q34430808-52EDD233-6D41-4050-B55E-9B61B4646A31Q34432811-CBAD34EF-33C1-4EC1-8C84-D257379D79E5Q34997580-15548224-3D36-435B-9B97-BC77BEF57B84Q35000542-A163E216-A219-43D7-9C16-6F8FBDFA4F0EQ35036033-6A414E63-081C-47DC-A6D5-452DBA7B243AQ35038766-C2628EE7-8F51-4234-8367-B52633B51CFEQ35069896-5F8FD6C3-527D-4901-9A86-912A7C67F712Q35073445-18AB4F8A-33C5-4374-98E1-A535B7D885C4Q35203306-E377B755-23F3-4262-A3EC-9059D376C7B4Q35495173-FB24E6A6-5364-4541-B22E-028FE5176A9EQ35690676-8BEE4F2A-E354-4A2F-80C8-C2CE81904C68Q35770411-D9D29177-1836-4454-9886-2218DAE4A7F8Q35821098-C4C1FE6E-06EE-4556-A909-7BA4B098898AQ35835177-D01592D7-36F5-4A35-9CA8-958302661B1FQ35908482-D1446B23-0A2A-4A98-8C46-2556F4F2E997Q36000669-0DF9B47C-95F7-4401-8445-95EE7B31EA56Q36109812-924CAAC7-FB48-44F1-A0AF-58256F67CBB0Q36205998-8D4D6199-5FFC-4776-AFD6-BC5CD8778E95Q36341195-064136D1-FF2E-46F4-867E-AA1E7DA28D55Q36402765-FADD3237-5C74-42FB-90F9-9F810A746A55Q36414181-2C97F5F8-8D0B-4B0D-AFE3-309920FA0ED0Q36459799-F079FAF9-74CA-4876-8997-6D86BBFBE7E5Q36494175-DA6300D2-6210-4B7E-AB0E-0176AA181B68Q36610417-D39EFF11-A5FF-4987-B6BC-08E81A11A4F6Q36613522-3FA0A8F2-B7BC-4AE4-9367-4823B4B77445Q36615447-12E6FBE1-4227-4BEE-886C-D359FA96DE2EQ36699005-68408FB0-4B26-4CA8-A962-F0C49FFC00DAQ36817519-073500B4-8D07-46CC-8559-75030728EC5BQ36826712-139DD6C2-9E30-4A6A-A855-BC35B4A3A236Q36839786-3A42E646-51A2-42D5-A4B3-1C6C8029396EQ36947265-719A240E-9545-4E7B-8E87-F8D2BC340939
P2860
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
POBASCAM, a population-based r ...... baseline data of 44,102 women.
@ast
POBASCAM, a population-based r ...... baseline data of 44,102 women.
@en
type
label
POBASCAM, a population-based r ...... baseline data of 44,102 women.
@ast
POBASCAM, a population-based r ...... baseline data of 44,102 women.
@en
prefLabel
POBASCAM, a population-based r ...... baseline data of 44,102 women.
@ast
POBASCAM, a population-based r ...... baseline data of 44,102 women.
@en
P2093
P2860
P356
P1476
POBASCAM, a population-based r ...... baseline data of 44,102 women.
@en
P2093
A Joan P Boeke
Adriaan J C van den Brule
Chris J L M Meijer
Feja J Voorhorst
Folkert J van Kemenade
Gladys R J Zandwijken
Hans J F Keuning
Krijn v Groningen
Lawrence Rozendaal
Mathilde E Boon
P2860
P304
P356
10.1002/IJC.20076
P577
2004-05-01T00:00:00Z